The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Systemic Lupus Erythematosus
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
The University of Arizona Arthritis Center, Tucson, Arizona, United States, 85724
Kaiser Permanente, Fontana, California, United States, 92335
Private Practice - Dr. Chandrakant V. Mehta, Hemet, California, United States, 92543
Arthritis & Osteoporosis Medical Center - La Palma, La Palma, California, United States, 90623
UCLA Clinical & Translational Research Center (CTRC), Los Angeles, California, United States, 90095
Private Practice - Dr. Hans Richard Barthel, Santa Barbara, California, United States, 93108
Denver Arthritis Clinic, Denver, Colorado, United States, 80230
Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut, United States, 06510
Rheumatology Assoc. Of South Florida, Boca Raton, Florida, United States, 33486
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2027-12-17